Press-release for stocks for kering for stro

| -21.79% | O: -0.59% H: 0.27% C: -1.83%
PPRUY | $36.0023 -0.11% 220K

| -21.79% | O: -1.85% H: 0.2% C: -0.07%
PCVX | $60.82 0.33% 0.33% 1.3M

| -12.94% | O: 0.2% H: 0.18% C: -0.42%
STRO | $3.635 -3.58% -3.71% 520K

| -23.23% | O: 0.2% H: 1.81% C: -3.43%
vax-24 disease pneumococcal study

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
Published: 2024-01-29 (Crawled : 13:30) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K

| -12.79% | O: 0.92% H: 0.76% C: -1.38%
PPRUY | $36.0023 -0.11% 220K

| -13.45% | O: -0.55% H: 1.4% C: 1.28%
PCVX | $60.82 0.33% 0.33% 1.3M

| -2.92% | O: 0.26% H: 6.59% C: 6.23%
STRO | $3.635 -3.58% -3.71% 520K

| -19.15% | O: -0.43% H: 6.84% C: 6.62%
vax-31 disease pneumococcal study

Vaxcyte Appoints Whitney Jones as Chief People Officer
Published: 2024-01-16 (Crawled : 21:00) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K

| -7.74% | O: -2.87% H: 0.1% C: -0.62%
PPRUY | $36.0023 -0.11% 220K

| -7.23% | O: -3.45% H: 0.61% C: 0.53%
PCVX | $60.82 0.33% 0.33% 1.3M

| 1.1% | O: -1.81% H: 3.73% C: 3.69%
STRO | $3.635 -3.58% -3.71% 520K

| -1.81% | O: -2.07% H: 8.71% C: 8.44%
jones

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
Published: 2024-01-04 (Crawled : 21:00) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K

| -14.2% | O: -1.72% H: 1.77% C: -1.05%
PPRUY | $36.0023 -0.11% 220K

| -13.08% | O: -1.13% H: 1.81% C: 0.95%
PCVX | $60.82 0.33% 0.33% 1.3M

| -2.97% | O: -2.53% H: 0.56% C: -4.66%
STRO | $3.635 -3.58% -3.71% 520K

| -14.41% | O: -4.28% H: 0.0% C: -17.88%
pneumococcal vaccine update potential

Vaxcyte Appoints Jacks Lee to Board of Directors
Published: 2023-11-28 (Crawled : 14:00) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K

| -18.51% | O: -1.83% H: 1.83% C: -2.33%
SNYNF | News | $92.7 -2.18% 600K

| -2.28% | O: -1.89% H: 0.02% C: 0.02%
PPRUY | $36.0023 -0.11% 220K

| -18.54% | O: -2.83% H: 1.05% C: 0.51%
PCVX | $60.82 0.33% 0.33% 1.3M

| 24.54% | O: -1.82% H: 1.91% C: 1.75%
STRO | $3.635 -3.58% -3.71% 520K

| 66.67% | O: 6.14% H: 1.24% C: -5.79%
SNY | News | $46.32 2.05% 2.01% 3.3M

| -4.49% | O: -1.41% H: 0.87% C: 0.0%
GTHX | $4.12 -1.2% -1.21% 730K

| 154.27% | O: -0.61% H: 4.91% C: 3.68%

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
Published: 2023-11-27 (Crawled : 21:00) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K

| -18.51% | O: -1.83% H: 1.83% C: -2.33%
PPRUY | $36.0023 -0.11% 220K

| -18.54% | O: -2.83% H: 1.05% C: 0.51%
PCVX | $60.82 0.33% 0.33% 1.3M

| 24.54% | O: -1.82% H: 1.91% C: 1.75%
STRO | $3.635 -3.58% -3.71% 520K

| 66.67% | O: 6.14% H: 1.24% C: -5.79%
vaccine control biopharma agreement

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-11-09 (Crawled : 13:30) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K

| -16.85% | O: -1.41% H: 1.77% C: -1.32%
PPRUY | $36.0023 -0.11% 220K

| -16.35% | O: 1.28% H: 0.21% C: -1.4%
PCVX | $60.82 0.33% 0.33% 1.3M

| 23.38% | O: 0.59% H: 0.63% C: -5.62%
STRO | $3.635 -3.58% -3.71% 520K

| 56.38% | O: 4.12% H: 0.0% C: -11.07%
vax-31 disease pneumococcal study

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-06 (Crawled : 21:00) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K

| -13.84% | O: 4.04% H: 0.01% C: -0.94%
PPRUY | $36.0023 -0.11% 220K

| -15.6% | O: -0.66% H: 1.13% C: 0.77%
PCVX | $60.82 0.33% 0.33% 1.3M

| 29.39% | O: -0.52% H: 7.4% C: 4.69%
STRO | $3.635 -3.58% -3.71% 520K

| 41.79% | O: 1.49% H: 0.74% C: -3.68%
business update financial results

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-10-19 (Crawled : 12:30) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K

| -17.42% | O: -0.57% H: 1.09% C: 0.98%
PPRUY | $36.0023 -0.11% 220K

| -15.86% | O: 1.4% H: 0.53% C: -0.81%
PCVX | $60.82 0.33% 0.33% 1.3M

| 35.63% | O: 0.24% H: 2.54% C: 0.78%
STRO | $3.635 -3.58% -3.71% 520K

| 7.95% | O: -0.28% H: 0.0% C: -6.27%
vax-31 fda drug disease pneumococcal clearance application

Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
Published: 2023-10-16 (Crawled : 12:00) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K

| -13.63% | O: 1.46% H: 2.75% C: 2.06%
PPRUY | $36.0023 -0.11% 220K

| -15.22% | O: 0.61% H: 1.43% C: 1.31%
PCVX | $60.82 0.33% 0.33% 1.3M

| 35.72% | O: 0.8% H: 2.8% C: 1.1%
STRO | $3.635 -3.58% -3.71% 520K

| -3.55% | O: 1.52% H: 0.25% C: -7.25%
pneumococcal global collaboration commercial

Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
Published: 2023-08-08 (Crawled : 20:00) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K

| -35.03% | O: 1.36% H: 3.13% C: 2.6%
PPRUY | $36.0023 -0.11% 220K

| -36.61% | O: 0.62% H: 0.32% C: -0.47%
PCVX | $60.82 0.33% 0.33% 1.3M

| 27.75% | O: -1.78% H: 2.91% C: -2.19%
STRO | $3.635 -3.58% -3.71% 520K

| -7.77% | O: 0.0% H: 2.91% C: 2.43%
business update financial results

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-07-11 (Crawled : 12:20) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K

| -31.45% | O: 3.26% H: 0.0% C: -0.57%
PPRUY | $36.0023 -0.11% 220K

| -32.03% | O: 1.02% H: 0.9% C: 0.75%
PCVX | $60.82 0.33% 0.33% 1.3M

| 31.13% | O: -2.77% H: 2.2% C: 0.65%
STRO | $3.635 -3.58% -3.71% 520K

| -20.0% | O: -1.47% H: 1.71% C: 0.64%
vax-24 disease pneumococcal ongoing study

Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
Published: 2023-04-17 (Crawled : 11:00) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K

| -41.95% | O: 0.05% H: 1.69% C: -1.81%
PPRUY | $36.0023 -0.11% 220K

| -43.22% | O: -2.08% H: 0.03% C: -0.19%
PCVX | $60.82 0.33% 0.33% 1.3M

| 71.04% | O: 15.18% H: 6.42% C: 0.71%
STRO | $3.635 -3.58% -3.71% 520K

| -13.64% | O: 0.68% H: 8.13% C: 5.64%
vax-24 pneumococcal vaccine positive study phase 2

Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-03-30 (Crawled : 15:00) - biospace.com/
PPRUF | $358.55 37.56% 1.5K

| -42.24% | O: 2.52% H: 2.74% C: 2.74%
PPRUY | $36.0023 -0.11% 220K

| -43.2% | O: 1.88% H: 1.04% C: 0.57%
PCVX | $60.82 0.33% 0.33% 1.3M

| 69.42% | O: -0.52% H: 0.55% C: -1.06%
STRO | $3.635 -3.58% -3.71% 520K

| -20.34% | O: -1.05% H: 2.86% C: -5.08%
vax-24 disease pneumococcal study phase 2

Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Published: 2023-02-27 (Crawled : 01:00) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K

| -39.84% | O: -2.33% H: 1.29% C: 0.07%
PPRUY | $36.0023 -0.11% 220K

| -39.52% | O: -1.23% H: 0.49% C: -0.14%
PCVX | $60.82 0.33% 0.33% 1.3M

| 47.59% | O: -5.44% H: 2.81% C: 2.42%
STRO | $3.635 -3.58% -3.71% 520K

| -33.68% | O: 0.0% H: 5.06% C: -1.57%
year financial update results

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
PPRUF | $358.55 37.56% 1.5K

| -43.3% | O: -3.64% H: 3.09% C: 1.33%
PPRUY | $36.0023 -0.11% 220K

| -43.19% | O: -1.68% H: 1.12% C: -0.58%
PCVX | $60.82 0.33% 0.33% 1.3M

| 41.18% | O: -0.93% H: 1.96% C: 0.55%
STRO | $3.635 -3.58% -3.71% 520K

| -38.91% | O: -1.13% H: 5.37% C: -0.98%
vax-24 fda clearance drug disease application pneumococcal

Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-01-05 (Crawled : 15:00) - biospace.com/
PPRUF | $358.55 37.56% 1.5K

| -32.19% | O: 1.3% H: 2.07% C: 1.45%
PPRUY | $36.0023 -0.11% 220K

| -33.54% | O: 0.44% H: 0.55% C: -0.17%
PCVX | $60.82 0.33% 0.33% 1.3M

| 33.23% | O: -0.13% H: 0.45% C: -1.58%
STRO | $3.635 -3.58% -3.71% 520K

| -53.09% | O: -0.86% H: 7.35% C: 5.23%
vax-24 fda designation disease granted therapy pneumococcal

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
Published: 2022-12-20 (Crawled : 22:00) - sutrobio.com
PPRUF | $358.55 37.56% 1.5K

| -27.44% | O: 2.83% H: 2.66% C: -0.36%
PPRUY | $36.0023 -0.11% 220K

| -27.4% | O: 1.46% H: 1.58% C: 0.82%
PCVX | $60.82 0.33% 0.33% 1.3M

| 38.92% | O: 0.22% H: 3.45% C: 3.2%
STRO | $3.635 -3.58% -3.71% 520K

| -43.11% | O: 4.79% H: 1.43% C: 0.0%
biopharma grant agreement

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
Published: 2022-10-24 (Crawled : 11:00) - biospace.com/
PPRUF | $358.55 37.56% 1.5K

| -18.53% | O: 0.55% H: 3.41% C: -0.9%
PPRUY | $36.0023 -0.11% 220K

| -20.27% | O: -0.01% H: 0.83% C: -0.01%
PCVX | $60.82 0.33% 0.33% 1.3M

| 203.35% | O: 70.8% H: 2.7% C: -6.12%
STRO | $3.635 -3.58% -3.71% 520K

| -32.62% | O: 0.71% H: 14.96% C: 13.91%
candidate disease topline vaccine positive study pneumococcal

Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-08 (Crawled : 22:00) - biospace.com/
PPRUF | $358.55 37.56% 1.5K

| -33.43% | O: 5.95% H: 0.0% C: -1.24%
PPRUY | $36.0023 -0.11% 220K

| -35.01% | O: 1.46% H: 0.62% C: -0.53%
PCVX | $60.82 0.33% 0.33% 1.3M

| 140.76% | O: 0.62% H: 0.13% C: -0.65%
STRO | $3.635 -3.58% -3.71% 520K